GL1X · GenesisL1 explorer

MolNFT v1 · #176623 · protein

Anthranilate phosphoribosyltransferase variant GLY141ASN from saccharomyces cerevisiae in complex with 4-fluoroanthranilate

7DSR: “Anthranilate phosphoribosyltransferase variant GLY141ASN from saccharomyces cerevisiae in complex with…”. X-ray diffraction, 1 ligand (FA0), 6 pockets (best druggability 0.65). MolNFT v1 #176623 on GenesisL1: 3D structure, binding…

PDB
7DSR
Type
protein
Length
711 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
Anthranilate phosphoribosyltransferase
EC
2.4.2.18
UniProt
P07285
Ligands
FA0
Pockets
6 · best druggability 0.65

Structure

x-ray diffraction · 2 distinct chains · 51% helix, 13% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
AAnthranilate phosphoribosyltransferase (EC 2.4.2.18)protein35551% helix, 14% strandP07285
BAnthranilate phosphoribosyltransferase (EC 2.4.2.18)protein35652% helix, 13% strandP07285

Ligands and binding sites

  • FA0 · 2-amino-4-fluorobenzoic acid · ligand · chains A

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

6 pockets found on a 1 Å grid, 2 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
13870.650.7945FA0
23820.630.7844empty
3740.360.7617empty
4740.340.7516empty
5720.320.7522empty

Interfaces

1 interface between chains.

  • A–B · 1238 Ų buried · 10 hydrogen bonds · protein-protein

Compared structures

  • 7DSR · Anthranilate phosphoribosyltransferase variant Gly141Asn from Saccharomyces cerevisiae in… · the same entry in another collection · chain A against A, TM-score 1.00
  • P07285 · AlphaFold monomer V2.0 prediction for anthranilate phosphoribosyltransferase (P07285) · a predicted model of the same protein · chain B against A, TM-score 0.98

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.